SCHEMBL23212044

SCHEMBL23212044

O=C(O)N1CCC(c2ccnc(C3CC3)c2)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC4 P56524 4/20 0.53
HDAC3 O15379 1/20 0.53
HDAC7 Q8WUI4 1/20 0.53
HDAC8 Q9BY41 1/20 0.53
HDAC6 Q9UBN7 1/20 0.53
HDAC9 Q9UKV0 1/20 0.53
HDAC5 Q9UQL6 1/20 0.53
PROKR1 Q8TCW9 1/20 0.45
SCD5 Q86SK9 4/20 0.42
QDPR P09417 2/20 0.41
LMNA P02545 2/20 0.40
MAP3K12 Q12852 1/20 0.39
CHRNA7 P36544 1/20 0.38
SLC22A12 Q96S37 1/20 0.38
SCD O00767 1/20 0.38
KDM4C Q9H3R0 2/20 0.37
LNPEP Q9UIQ6 1/20 0.36
KDM2B Q8NHM5 1/20 0.36
TLR9 Q9NR96 1/20 0.36
TLR8 Q9NR97 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15535562 0.82 GABRP (0.42) HDAC4HDAC3HDAC7HDAC8HDAC6
SCHEMBL15534859 0.82 PROKR1 (0.47) HDAC4HDAC3HDAC7HDAC8HDAC6
SCHEMBL21381792 0.80 HTT (0.51)
SCHEMBL1856770 0.78 LMNA (0.55) SCD5LMNASCD
SCHEMBL4074303 0.77 HSD11B1 (0.53) SCD5
SCHEMBL19910128 0.76 CHRNA7 (0.52) HDAC4HDAC3HDAC7HDAC8HDAC6
SCHEMBL30711201 0.74 EPHX2 (0.49) SCD5SCD
SCHEMBL15547675 0.73 HDAC4 (0.76) HDAC4HDAC3HDAC7HDAC8HDAC6
SCHEMBL27964718 0.73 CAMKK2 (0.41) HDAC4HDAC3HDAC7HDAC8HDAC6
SCHEMBL23235678 0.73 KMT2A (0.38) PROKR1SCD5LMNAMAP3K12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230117324-A1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2023-04-20 US disclosed
EP-3768684-B1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS HOFFMANN LA ROCHE (CH) 2023-02-22 EP disclosed
US-20210107920-A1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2021-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210107920-A1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS MGLL, LPL, LIPC HDAC4 3683/4885HDAC3 1871/4885HDAC7 2803/4885
US-20230117324-A1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS MGLL, LPL, LIPC HDAC4 3683/4885HDAC3 1871/4885HDAC7 2803/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.